Skip to content

ENTRADA THERAPEUTICS, INC.

TRDA

CIK 0001689375

← back to feed
Revenue (TTM)
$25M
−87.9% YoY Q1 Apr 2026
Net Income (TTM)
−$144.3M
−319.0% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$3.47
−306.5% YoY Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
-632.0%
Q1 Apr 2026
Net Margin
-577.3%
Q1 Apr 2026
Free Cash Flow (TTM)
$93.98M
Q1 Apr 2026
Cash
$76.44M
Q1 Apr 2026
Total Debt
—
Q1 Apr 2026
Shares Outstanding
38.82M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings